首页|Chimeric antigen receptor-immune cells against solid tumors:Structures,mechanisms,recent advances,and future developments

Chimeric antigen receptor-immune cells against solid tumors:Structures,mechanisms,recent advances,and future developments

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
The advent of chimeric antigen receptor(CAR)-T cell immunotherapies has led to breakthroughs in the treatment of hematological malignancies.However,their success in treating solid tumors has been limited.CAR-natural killer(NK)cells have several advantages over CAR-T cells because NK cells can be made from pre-existing cell lines or allogeneic NK cells with a mismatched major histocompatibility complex(MHC),which means they are more likely to become an"off-the-shelf"product.Moreover,they can kill cancer cells via CAR-dependent/independent pathways and have limited toxicity.Macrophages are the most malleable immune cells in the body.These cells can efficiently infiltrate into tumors and are present in large numbers in tumor microenvironments(TMEs).Importantly,CAR-macrophages(CAR-Ms)have recently yielded exciting preclinical results in several solid tumors.Nevertheless,CAR-T,CAR-NK,and CAR-M all have their own advantages and limitations.In this review,we systematically discuss the current status,progress,and the major hurdles of CAR-T cells,CAR-NK cells,and CAR-M as they relate to five aspects:CAR structure,therapeutic mechanisms,the latest research progress,current challenges and solutions,and comparison according to the existing research in order to provide a reasonable option for treating solid tumors in the future.

ImmunotherapyChimeric antigen receptor-T cellsChimeric antigen receptor-NK cellsChimeric antigen receptor-macrophageSolid tumors

Xudong Li、Wei Li、Linping Xu、Yongping Song

展开 >

Department of Hematology,The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Zhengzhou,Henan 450008,China

Academy of Medical Sciences,Zhengzhou University,Zhengzhou,Henan 450052,China

Department of Hematology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan 450052,China

Natural Science Foundation of ChinaChina Postdoctoral Science FoundationChina Postdoctoral Science FoundationYoung Postdoctoral Innovators in Henan ProvinceHenan Province Medical Science and Technology Research ProjectHenan Province Medical Science and Technology Research Project

822701492022T1505922021M692930SBGJ202102063LHGJ20220305

2024

10.1097/CM9.0000000000002818

中华医学杂志(英文版)
中华医学会

中华医学杂志(英文版)

CSTPCD
影响因子：0.838
ISSN：0366-6999
年,卷(期)：2024.137(11)
  • 4